Our business is built on an unwavering commitment to integrity and compliance, which is demonstrated by our staff members every day through their words, decisions and actions.

This requires preserving our heritage of high ethical values and standards, ensuring accountability for our actions, and putting the patient first. Quite simply, it requires doing things right and doing the right things.

This approach is woven through all facets of our organization by robust governance practices, global policies, performance management systems, training, and ongoing monitoring and remediation. It is also built on a culture of transparency and engagement with stakeholders.

Program Elements within A Healthy Amgen Pillar

Effective corporate governance is critical for both our long-term performance and maintaining stakeholder trust.

To deliver on our mission, we must conduct our business ethically and with integrity, while also ensuring compliance with the laws and regulations that govern our business and industry.

Amgen aims to discover, develop and deliver transformative medicines to address some of the leading causes of death and disability worldwide, and to do so ethically and in accordance with our internal policies and external standards.

Amgen is committed to the safety of patients and the safe and effective use of our products.

Learn more about Product Quality.

Learn more about Patient Safety.

We have robust systems and processes in place that support the ethical use, management and protection of all personal information and data entrusted to us.

2021 Highlights
class 1 or 2 product recalls*
Amgen employees served as cybersecurity ambassadors, representing 34 countries and every function within the Company
of employees trained on the Code of Conduct

*Class 1 recall is defined by the U.S. Food and Drug Administration (FDA) as a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death. A Class 2 recall is defined by the FDA as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.